IGC Pharma (IGC) Cash from Investing Activities (2010 - 2025)
IGC Pharma (IGC) posted quarterly Cash from Investing Activities of -$374000.0 for Q3 2025, down 475.38% year-over-year from $99631.1 in Q3 2024, and down 164.48% quarter-over-quarter from $580000.0 in Q2 2025.
IGC Pharma (IGC) Cash from Investing Activities (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Cash from Investing Activities for 16 consecutive years, with -$374000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Investing Activities fell 475.38% year-over-year to -$374000.0; the TTM figure through Sep 2025 stood at -$40000.0 (up 93.1% YoY), while the FY2026 annual figure was -$170000.0, up 61.54% from the prior year.
- Cash from Investing Activities slipped to -$374000.0 in Q3 2025 per IGC's latest filing, from $580000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $1.9 million in Q1 2021 and bottomed at -$553000.0 in Q1 2022.
- Historically, Cash from Investing Activities has averaged $20947.4 across 5 years, with a median of -$65000.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities plunged 2520.0% — and 2025, when it soared 542.75%.
- IGC Pharma's Cash from Investing Activities stood at -$49000.0 in 2021, then surged by 65.31% to -$17000.0 in 2022, then tumbled by 258.82% to -$61000.0 in 2023, then sank by 70.49% to -$104000.0 in 2024, then sank by 259.62% to -$374000.0 in 2025.
- Business Quant data shows IGC's Cash from Investing Activities at -$374000.0 in Q3 2025, $580000.0 in Q2 2025, and -$142000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -374,000.00 |
| Sep 30, 2025 | -374,000.00 |
| Jun 30, 2025 | 580,000.00 |
| Jun 30, 2025 | 580,000.00 |
| Mar 31, 2025 | -142,000.00 |
| Mar 31, 2025 | -142,000.00 |
| Dec 31, 2024 | -104,000.00 |
| Dec 31, 2024 | -104,000.00 |
| Sep 30, 2024 | -65,000.00 |
| Sep 30, 2024 | -65,000.00 |
| Jun 30, 2024 | -131,000.00 |
| Jun 30, 2024 | -131,000.00 |
| Mar 31, 2024 | -323,000.00 |
| Mar 31, 2024 | -323,000.00 |
| Dec 31, 2023 | -61,000.00 |
| Dec 31, 2023 | -61,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Jun 30, 2023 | -5,000.00 |